Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia.
Zhang H, Alberich-Jorda M, Amabile G, Yang H, Staber PB, Di Ruscio A, Welner RS, Ebralidze A, Zhang J, Levantini E, Lefebvre V, Valk PJ, Delwel R, Hoogenkamp M, Nerlov C, Cammenga J, Saez B, Scadden DT, Bonifer C, Ye M, Tenen DG. Zhang H, et al. Among authors: staber pb. Cancer Cell. 2013 Nov 11;24(5):575-88. doi: 10.1016/j.ccr.2013.09.018. Epub 2013 Oct 31. Cancer Cell. 2013. PMID: 24183681 Free PMC article.
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, Schetelig J, von Tresckow J, Vehling-Kaiser U, Gaska T, Wendtner CM, Chapuy B, Fischer K, Kreuzer KA, Stilgenbauer S, Staber P, Niemann C, Hallek M, Eichhorst B. Al-Sawaf O, et al. Nat Med. 2024 Jan;30(1):240-248. doi: 10.1038/s41591-023-02722-9. Epub 2023 Dec 9. Nat Med. 2024. PMID: 38071379 Free PMC article. Clinical Trial.
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Belada D, Kopeckova K, Bergua Burgues JM, Stevens D, André M, Persona EP, Pichler P, Staber PB, Trneny M, Duell J, Waldron-Lynch M, Wagner S, Mukhopadhyay A, Dirnberger-Hertweck M, Burke JM, Nowakowski GS. Belada D, et al. Among authors: staber pb. Blood. 2023 Oct 19;142(16):1348-1358. doi: 10.1182/blood.2023020637. Blood. 2023. PMID: 37369099 Free PMC article. Clinical Trial.
The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma.
Worel N, Grabmeier-Pfistershammer K, Kratzer B, Schlager M, Tanzmann A, Rottal A, Körmöczi U, Porpaczy E, Staber PB, Skrabs C, Herkner H, Gudipati V, Huppa JB, Salzer B, Lehner M, Saxenhuber N, Friedberg E, Wohlfarth P, Hopfinger G, Rabitsch W, Simonitsch-Klupp I, Jäger U, Pickl WF. Worel N, et al. Among authors: staber pb. Front Immunol. 2023 Jan 9;13:1004703. doi: 10.3389/fimmu.2022.1004703. eCollection 2022. Front Immunol. 2023. PMID: 36700229 Free PMC article.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Fürstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers AM, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber PB, Tadmor T, Levin MD, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Janssens A, Christiansen I, Nösslinger T, Baumann M, Hebart H, Gaska T, Regelink JC, Dompeling EC, Lindström V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink AM, Fischer K, Wendtner CM, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann CU, Hallek M, Eichhorst B, Kreuzer KA, Kater AP. Fürstenau M, et al. Among authors: staber pb. Blood. 2023 Aug 3;142(5):446-459. doi: 10.1182/blood.2023019634. Blood. 2023. PMID: 37172204 Clinical Trial.
CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS.
Bauer K, Machherndl-Spandl S, Kazianka L, Sadovnik I, Gültekin S, Suessner S, Proell J, Lauf J, Hoermann G, Eisenwort G, Häfner N, Födermayr-Mayrleitner M, Schmolke AS, van der Kouwe E, Platzbecker U, Lion T, Weltermann A, Zach O, Webersinke G, Germing U, Gabriel C, Sperr WR, Béné MC, Staber PB, Bettelheim P, Valent P. Bauer K, et al. Among authors: staber pb. Leukemia. 2023 Nov;37(11):2250-2260. doi: 10.1038/s41375-023-02015-7. Epub 2023 Sep 6. Leukemia. 2023. PMID: 37673973 Free PMC article.
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
Herling M, Dearden C, Zaja F, El-Sharkawi D, Ding W, Bellido M, Khot A, Tick L, Jacobsen E, Eyre TA, Roos-Weil D, Kadia T, Lucchini E, Pflug N, Davids MS, Pena G, Mukherjee N, Badawi M, Vizkelety T, Staber PB. Herling M, et al. Among authors: staber pb. Blood Adv. 2024 Feb 27;8(4):842-845. doi: 10.1182/bloodadvances.2023012248. Blood Adv. 2024. PMID: 38190628 Free PMC article. Clinical Trial. No abstract available.
Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells.
Staber PB, Zhang P, Ye M, Welner RS, Nombela-Arrieta C, Bach C, Kerenyi M, Bartholdy BA, Zhang H, Alberich-Jordà M, Lee S, Yang H, Ng F, Zhang J, Leddin M, Silberstein LE, Hoefler G, Orkin SH, Göttgens B, Rosenbauer F, Huang G, Tenen DG. Staber PB, et al. Mol Cell. 2013 Mar 7;49(5):934-46. doi: 10.1016/j.molcel.2013.01.007. Epub 2013 Feb 8. Mol Cell. 2013. PMID: 23395001 Free PMC article.
103 results